7.17 USD
↗ 0.25 (3.69%)PRE MARKET (AS OF 04:20 AM EDT)
KMDA is currently priced at $7.17. The technical outlook is "Strong Sell" and the fundamental picture shows "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, KMDA trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Jul 16, 2026.
Open?$6.91
High?$7.00
Low?$6.91
Prev. Close?$6.91
Volume?403
Avg. Volume?37.4K
VWAP?$7.00
Rel. Volume?0.01x
Bid / Ask
Bid?$5.93 × 100
Ask?$7.94 × 100
Spread?$2.01
Midpoint?$6.94
Valuation & Ratios
Market Cap?398.7M
Shares Out?N/A
Float?31.4M
Float %?54.6%
P/E Ratio?N/A
P/B Ratio?5.97
EPS?-$0.05
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?50
Short Sent.?68
Piotroski F-Score?0/9Weak
Altman Z-Score?6.19Safe
Confidence?38%Very Low
Short InterestModerate
Short % of Float?0.49%Low
Short Interest?153.3K
Days to Cover?3.5
Free Float31.4M
Avg Daily Volume43.4K
Settlement Date2026-06-30
Financial Health
Current Ratio?2.83Strong
Quick Ratio?1.89Adequate
Cash Ratio?0.37Low
Debt/Equity?0.03Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?5.97FAIR▾
Peers100
S&P31
P/S?6.70FAIR▾
Peers100
S&P18
P/FCF?N/A▾
EV/EBITDA?-5,916.3CHEAP▾
S&P97
EV/Sales?6.56HIGH▾
Peers100
S&P23
Returns & Efficiency
ROE?-4.3%WEAK▾
S&P11
ROA?-2.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$390.5M
Fundamentals ratios updated end of day